HXB13_HUMAN
ID HXB13_HUMAN Reviewed; 284 AA.
AC Q92826; B2R878; Q96QM4; Q99810;
DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT 19-JUL-2004, sequence version 2.
DT 03-AUG-2022, entry version 194.
DE RecName: Full=Homeobox protein Hox-B13;
GN Name=HOXB13;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA].
RX PubMed=8756292; DOI=10.1242/dev.122.8.2475;
RA Zeltser L.M., Desplan C., Heintz N.;
RT "Hoxb-13: a new Hox gene in a distant region of the HOXB cluster maintains
RT colinearity.";
RL Development 122:2475-2484(1996).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA].
RX PubMed=9665387; DOI=10.1046/j.1523-1747.1998.00238.x;
RA Stelnicki E.J., Arbeit J., Cass D.L., Saner C., Harrison M., Largman C.;
RT "Modulation of the human homeobox genes PRX-2 and HOXB13 in scarless fetal
RT wounds.";
RL J. Invest. Dermatol. 111:57-63(1998).
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA Phelan M., Farmer A.;
RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN [4]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC TISSUE=Prostate;
RX PubMed=14702039; DOI=10.1038/ng1285;
RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA Isogai T., Sugano S.;
RT "Complete sequencing and characterization of 21,243 full-length human
RT cDNAs.";
RL Nat. Genet. 36:40-45(2004).
RN [5]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA Hunkapiller M.W., Myers E.W., Venter J.C.;
RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN [6]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC TISSUE=Prostate;
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [7] {ECO:0007744|PDB:2CRA}
RP STRUCTURE BY NMR OF 217-273.
RG RIKEN structural genomics initiative (RSGI);
RT "Solution structure of the homeobox domain of human homeo box B13.";
RL Submitted (NOV-2005) to the PDB data bank.
RN [8] {ECO:0007744|PDB:5EDN, ECO:0007744|PDB:5EEA, ECO:0007744|PDB:5EG0}
RP X-RAY CRYSTALLOGRAPHY (2.19 ANGSTROMS) OF 209-284 IN COMPLEX WITH MEIS2 AND
RP DNA, SUBUNIT, AND DNA-BINDING.
RA Morgunova E., Yin Y., Jolma A., Popov A., Taipale J.;
RT "Molecular basis of recognition of two distinct DNA sequences by a single
RT transcription factor.";
RL Submitted (OCT-2015) to the PDB data bank.
RN [9] {ECO:0007744|PDB:5EF6, ECO:0007744|PDB:5EGO}
RP X-RAY CRYSTALLOGRAPHY (2.54 ANGSTROMS) OF 217-278 IN COMPLEX WITH MEIS1 AND
RP METHYLATED DNA, SUBUNIT, AND DNA-BINDING.
RX PubMed=28473536; DOI=10.1126/science.aaj2239;
RA Yin Y., Morgunova E., Jolma A., Kaasinen E., Sahu B., Khund-Sayeed S.,
RA Das P.K., Kivioja T., Dave K., Zhong F., Nitta K.R., Taipale M., Popov A.,
RA Ginno P.A., Domcke S., Yan J., Schubeler D., Vinson C., Taipale J.;
RT "Impact of cytosine methylation on DNA binding specificities of human
RT transcription factors.";
RL Science 356:0-0(2017).
RN [10]
RP VARIANT MET-41.
RX PubMed=11857506; DOI=10.1002/tera.10009;
RA Kosaki K., Kosaki R., Suzuki T., Yoshihashi H., Takahashi T., Sasaki K.,
RA Tomita M., McGinnis W., Matsuo N.;
RT "Complete mutation analysis panel of the 39 human HOX genes.";
RL Teratology 65:50-62(2002).
RN [11]
RP VARIANT PC GLU-84.
RX PubMed=22714738; DOI=10.1158/1055-9965.epi-12-0495;
RA Breyer J.P., Avritt T.G., McReynolds K.M., Dupont W.D., Smith J.R.;
RT "Confirmation of the HOXB13 G84E germline mutation in familial prostate
RT cancer.";
RL Cancer Epidemiol. Biomarkers Prev. 21:1348-1353(2012).
RN [12]
RP INVOLVEMENT IN PC, VARIANT PC GLU-84, AND VARIANTS ASP-88; PRO-144; CYS-216
RP AND GLY-229.
RX PubMed=22236224; DOI=10.1056/nejmoa1110000;
RA Ewing C.M., Ray A.M., Lange E.M., Zuhlke K.A., Robbins C.M., Tembe W.D.,
RA Wiley K.E., Isaacs S.D., Johng D., Wang Y., Bizon C., Yan G., Gielzak M.,
RA Partin A.W., Shanmugam V., Izatt T., Sinari S., Craig D.W., Zheng S.L.,
RA Walsh P.C., Montie J.E., Xu J., Carpten J.D., Isaacs W.B., Cooney K.A.;
RT "Germline mutations in HOXB13 and prostate-cancer risk.";
RL N. Engl. J. Med. 366:141-149(2012).
RN [13]
RP INVOLVEMENT IN PC, AND VARIANT PC GLU-84.
RX PubMed=23292082; DOI=10.1158/1055-9965.epi-12-1000-t;
RA Laitinen V.H., Wahlfors T., Saaristo L., Rantapero T., Pelttari L.M.,
RA Kilpivaara O., Laasanen S.L., Kallioniemi A., Nevanlinna H., Aaltonen L.,
RA Vessella R.L., Auvinen A., Visakorpi T., Tammela T.L., Schleutker J.;
RT "HOXB13 G84E mutation in Finland: population-based analysis of prostate,
RT breast, and colorectal cancer risk.";
RL Cancer Epidemiol. Biomarkers Prev. 22:452-460(2013).
RN [14]
RP INVOLVEMENT IN PC, AND VARIANT PC GLU-84.
RX PubMed=23064873; DOI=10.1007/s00439-012-1229-4;
RG International Consortium for Prostate Cancer Genetics;
RA Xu J., Lange E.M., Lu L., Zheng S.L., Wang Z., Thibodeau S.N.,
RA Cannon-Albright L.A., Teerlink C.C., Camp N.J., Johnson A.M., Zuhlke K.A.,
RA Stanford J.L., Ostrander E.A., Wiley K.E., Isaacs S.D., Walsh P.C.,
RA Maier C., Luedeke M., Vogel W., Schleutker J., Wahlfors T., Tammela T.,
RA Schaid D., McDonnell S.K., DeRycke M.S., Cancel-Tassin G., Cussenot O.,
RA Wiklund F., Gronberg H., Eeles R., Easton D., Kote-Jarai Z.,
RA Whittemore A.S., Hsieh C.L., Giles G.G., Hopper J.L., Severi G.,
RA Catalona W.J., Mandal D., Ledet E., Foulkes W.D., Hamel N., Mahle L.,
RA Moller P., Powell I., Bailey-Wilson J.E., Carpten J.D., Seminara D.,
RA Cooney K.A., Isaacs W.B.;
RT "HOXB13 is a susceptibility gene for prostate cancer: results from the
RT international consortium for prostate cancer genetics (ICPCG).";
RL Hum. Genet. 132:5-14(2013).
RN [15]
RP INVOLVEMENT IN PC, AND VARIANT PC GLU-84.
RX PubMed=25629170; DOI=10.1371/journal.pgen.1004930;
RA Hoffmann T.J., Sakoda L.C., Shen L., Jorgenson E., Habel L.A., Liu J.,
RA Kvale M.N., Asgari M.M., Banda Y., Corley D., Kushi L.H.,
RA Quesenberry C.P. Jr., Schaefer C., Van Den Eeden S.K., Risch N.,
RA Witte J.S.;
RT "Imputation of the Rare HOXB13 G84E Mutation and Cancer Risk in a Large
RT Population-Based Cohort.";
RL PLoS Genet. 11:E1004930-E1004930(2015).
RN [16]
RP VARIANT PC GLU-84, AND VARIANT CYS-217.
RX PubMed=27424772; DOI=10.1038/srep30026;
RA Liu J., Prager-van der Smissen W.J., Schmidt M.K., Collee J.M.,
RA Cornelissen S., Lamping R., Nieuwlaat A., Foekens J.A., Hooning M.J.,
RA Verhoef S., van den Ouweland A.M., Hogervorst F.B., Martens J.W.,
RA Hollestelle A.;
RT "Recurrent HOXB13 mutations in the Dutch population do not associate with
RT increased breast cancer risk.";
RL Sci. Rep. 6:30026-30026(2016).
CC -!- FUNCTION: Sequence-specific transcription factor which is part of a
CC developmental regulatory system that provides cells with specific
CC positional identities on the anterior-posterior axis. Binds
CC preferentially to methylated DNA (PubMed:28473536).
CC {ECO:0000269|PubMed:28473536}.
CC -!- SUBUNIT: Heterodimer with MEIS1 (PubMed:28473536). Heterodimer with
CC MEIS2 (Ref.8). {ECO:0000269|PubMed:28473536, ECO:0000269|Ref.8}.
CC -!- INTERACTION:
CC Q92826; Q92993: KAT5; NbExp=3; IntAct=EBI-11317274, EBI-399080;
CC Q92826; Q8TAP4-4: LMO3; NbExp=3; IntAct=EBI-11317274, EBI-11742507;
CC Q92826; P17252: PRKCA; NbExp=3; IntAct=EBI-11317274, EBI-1383528;
CC Q92826; Q15047-2: SETDB1; NbExp=3; IntAct=EBI-11317274, EBI-9090795;
CC Q92826; P61981: YWHAG; NbExp=3; IntAct=EBI-11317274, EBI-359832;
CC -!- SUBCELLULAR LOCATION: Nucleus.
CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in
CC tissues of the prostate. Most prostate cancers are adenocarcinomas that
CC develop in the acini of the prostatic ducts. Other rare histopathologic
CC types of prostate cancer that occur in approximately 5% of patients
CC include small cell carcinoma, mucinous carcinoma, prostatic ductal
CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal
CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell
CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:22236224,
CC ECO:0000269|PubMed:22714738, ECO:0000269|PubMed:23064873,
CC ECO:0000269|PubMed:23292082, ECO:0000269|PubMed:25629170,
CC ECO:0000269|PubMed:27424772}. Note=Disease susceptibility is associated
CC with variants affecting the gene represented in this entry.
CC -!- SIMILARITY: Belongs to the Abd-B homeobox family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; U57052; AAC50664.1; -; mRNA.
DR EMBL; U81599; AAB39863.1; -; mRNA.
DR EMBL; BT007410; AAP36078.1; -; mRNA.
DR EMBL; AK313266; BAG36075.1; -; mRNA.
DR EMBL; CH471109; EAW94714.1; -; Genomic_DNA.
DR EMBL; BC007092; AAH07092.1; -; mRNA.
DR EMBL; BC070233; AAH70233.1; -; mRNA.
DR CCDS; CCDS11536.1; -.
DR RefSeq; NP_006352.2; NM_006361.5.
DR PDB; 2CRA; NMR; -; A=217-273.
DR PDB; 5EDN; X-ray; 3.20 A; A/B/G/J=209-284.
DR PDB; 5EEA; X-ray; 2.19 A; A/B/G/J=217-279.
DR PDB; 5EF6; X-ray; 3.00 A; A/B/G/J=217-278.
DR PDB; 5EG0; X-ray; 3.10 A; B=217-277.
DR PDB; 5EGO; X-ray; 2.54 A; B=217-277.
DR PDB; 5NO6; X-ray; 2.88 A; A/B=217-278.
DR PDBsum; 2CRA; -.
DR PDBsum; 5EDN; -.
DR PDBsum; 5EEA; -.
DR PDBsum; 5EF6; -.
DR PDBsum; 5EG0; -.
DR PDBsum; 5EGO; -.
DR PDBsum; 5NO6; -.
DR AlphaFoldDB; Q92826; -.
DR SMR; Q92826; -.
DR BioGRID; 115744; 20.
DR IntAct; Q92826; 17.
DR MINT; Q92826; -.
DR STRING; 9606.ENSP00000290295; -.
DR iPTMnet; Q92826; -.
DR PhosphoSitePlus; Q92826; -.
DR BioMuta; HOXB13; -.
DR DMDM; 50403792; -.
DR jPOST; Q92826; -.
DR MassIVE; Q92826; -.
DR MaxQB; Q92826; -.
DR PaxDb; Q92826; -.
DR PeptideAtlas; Q92826; -.
DR PRIDE; Q92826; -.
DR ProteomicsDB; 75504; -.
DR Antibodypedia; 3837; 271 antibodies from 29 providers.
DR DNASU; 10481; -.
DR Ensembl; ENST00000290295.8; ENSP00000290295.8; ENSG00000159184.8.
DR GeneID; 10481; -.
DR KEGG; hsa:10481; -.
DR MANE-Select; ENST00000290295.8; ENSP00000290295.8; NM_006361.6; NP_006352.2.
DR UCSC; uc002ioa.4; human.
DR CTD; 10481; -.
DR DisGeNET; 10481; -.
DR GeneCards; HOXB13; -.
DR HGNC; HGNC:5112; HOXB13.
DR HPA; ENSG00000159184; Group enriched (intestine, prostate).
DR MalaCards; HOXB13; -.
DR MIM; 176807; phenotype.
DR MIM; 604607; gene.
DR neXtProt; NX_Q92826; -.
DR OpenTargets; ENSG00000159184; -.
DR Orphanet; 1331; Familial prostate cancer.
DR PharmGKB; PA29388; -.
DR VEuPathDB; HostDB:ENSG00000159184; -.
DR eggNOG; KOG0487; Eukaryota.
DR GeneTree; ENSGT00940000159029; -.
DR HOGENOM; CLU_059940_1_0_1; -.
DR InParanoid; Q92826; -.
DR OMA; HPPDGCA; -.
DR OrthoDB; 1190384at2759; -.
DR PhylomeDB; Q92826; -.
DR TreeFam; TF330813; -.
DR PathwayCommons; Q92826; -.
DR SignaLink; Q92826; -.
DR SIGNOR; Q92826; -.
DR BioGRID-ORCS; 10481; 34 hits in 1094 CRISPR screens.
DR ChiTaRS; HOXB13; human.
DR EvolutionaryTrace; Q92826; -.
DR GeneWiki; HOXB13; -.
DR GenomeRNAi; 10481; -.
DR Pharos; Q92826; Tbio.
DR PRO; PR:Q92826; -.
DR Proteomes; UP000005640; Chromosome 17.
DR RNAct; Q92826; protein.
DR Bgee; ENSG00000159184; Expressed in rectum and 21 other tissues.
DR Genevisible; Q92826; HS.
DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR GO; GO:0005667; C:transcription regulator complex; IEA:Ensembl.
DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR GO; GO:0008327; F:methyl-CpG binding; IDA:UniProtKB.
DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR GO; GO:0043565; F:sequence-specific DNA binding; IDA:NTNU_SB.
DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR GO; GO:0001525; P:angiogenesis; IEP:UniProtKB.
DR GO; GO:0008544; P:epidermis development; TAS:ProtInc.
DR GO; GO:0060743; P:epithelial cell maturation involved in prostate gland development; IEA:Ensembl.
DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR GO; GO:0060527; P:prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis; IEA:Ensembl.
DR GO; GO:0040008; P:regulation of growth; IEA:Ensembl.
DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR GO; GO:0009611; P:response to wounding; TAS:ProtInc.
DR CDD; cd00086; homeodomain; 1.
DR InterPro; IPR009057; Homeobox-like_sf.
DR InterPro; IPR017970; Homeobox_CS.
DR InterPro; IPR001356; Homeobox_dom.
DR InterPro; IPR022067; HoxA13_N.
DR Pfam; PF00046; Homeodomain; 1.
DR Pfam; PF12284; HoxA13_N; 1.
DR SMART; SM00389; HOX; 1.
DR SUPFAM; SSF46689; SSF46689; 1.
DR PROSITE; PS00027; HOMEOBOX_1; 1.
DR PROSITE; PS50071; HOMEOBOX_2; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Developmental protein; Disease variant; DNA-binding;
KW Homeobox; Nucleus; Reference proteome; Transcription;
KW Transcription regulation.
FT CHAIN 1..284
FT /note="Homeobox protein Hox-B13"
FT /id="PRO_0000200160"
FT DNA_BIND 216..275
FT /note="Homeobox"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00108"
FT REGION 217..246
FT /note="Interaction with DNA"
FT /evidence="ECO:0000305|PubMed:28473536, ECO:0000305|Ref.8"
FT REGION 258..269
FT /note="Interaction with 5-mCpG DNA"
FT /evidence="ECO:0000305|PubMed:28473536"
FT REGION 270..273
FT /note="Interaction with DNA"
FT /evidence="ECO:0000305|PubMed:28473536, ECO:0000305|Ref.8"
FT VARIANT 41
FT /note="T -> M (in dbSNP:rs199799743)"
FT /evidence="ECO:0000269|PubMed:11857506"
FT /id="VAR_031849"
FT VARIANT 84
FT /note="G -> E (in PC; rare variant associated with disease
FT susceptibility; dbSNP:rs138213197)"
FT /evidence="ECO:0000269|PubMed:22236224,
FT ECO:0000269|PubMed:22714738, ECO:0000269|PubMed:23064873,
FT ECO:0000269|PubMed:23292082, ECO:0000269|PubMed:25629170,
FT ECO:0000269|PubMed:27424772"
FT /id="VAR_071866"
FT VARIANT 88
FT /note="Y -> D (found in prostate cancer samples; unknown
FT pathological significance)"
FT /evidence="ECO:0000269|PubMed:22236224"
FT /id="VAR_071867"
FT VARIANT 144
FT /note="L -> P (found in prostate cancer samples; unknown
FT pathological significance)"
FT /evidence="ECO:0000269|PubMed:22236224"
FT /id="VAR_071868"
FT VARIANT 216
FT /note="G -> C (found in prostate cancer samples; unknown
FT pathological significance; dbSNP:rs375917549)"
FT /evidence="ECO:0000269|PubMed:22236224"
FT /id="VAR_071869"
FT VARIANT 217
FT /note="R -> C (in dbSNP:rs139475791)"
FT /evidence="ECO:0000269|PubMed:27424772"
FT /id="VAR_077246"
FT VARIANT 229
FT /note="R -> G (found in prostate cancer samples; unknown
FT pathological significance; dbSNP:rs529100627)"
FT /evidence="ECO:0000269|PubMed:22236224"
FT /id="VAR_071870"
FT CONFLICT 138..139
FT /note="QP -> HA (in Ref. 1 and 2)"
FT /evidence="ECO:0000305"
FT CONFLICT 211
FT /note="C -> S (in Ref. 1; AAC50664)"
FT /evidence="ECO:0000305"
FT HELIX 225..237
FT /evidence="ECO:0007829|PDB:5EEA"
FT HELIX 243..253
FT /evidence="ECO:0007829|PDB:5EEA"
FT HELIX 257..275
FT /evidence="ECO:0007829|PDB:5EEA"
SQ SEQUENCE 284 AA; 30676 MW; 3EE5898449C33CFE CRC64;
MEPGNYATLD GAKDIEGLLG AGGGRNLVAH SPLTSHPAAP TLMPAVNYAP LDLPGSAEPP
KQCHPCPGVP QGTSPAPVPY GYFGGGYYSC RVSRSSLKPC AQAATLAAYP AETPTAGEEY
PSRPTEFAFY PGYPGTYQPM ASYLDVSVVQ TLGAPGEPRH DSLLPVDSYQ SWALAGGWNS
QMCCQGEQNP PGPFWKAAFA DSSGQHPPDA CAFRRGRKKR IPYSKGQLRE LEREYAANKF
ITKDKRRKIS AATSLSERQI TIWFQNRRVK EKKVLAKVKN SATP
